WO1995020389A1 - Benzoxazinones en tant qu'inhibiteurs de transcriptase inverse du vih - Google Patents

Benzoxazinones en tant qu'inhibiteurs de transcriptase inverse du vih Download PDF

Info

Publication number
WO1995020389A1
WO1995020389A1 PCT/US1995/001148 US9501148W WO9520389A1 WO 1995020389 A1 WO1995020389 A1 WO 1995020389A1 US 9501148 W US9501148 W US 9501148W WO 9520389 A1 WO9520389 A1 WO 9520389A1
Authority
WO
WIPO (PCT)
Prior art keywords
unsubstituted
substituted
chloro
hiv
compound
Prior art date
Application number
PCT/US1995/001148
Other languages
English (en)
Inventor
Steven D. Young
Susan F. Britcher
Linda S. Payne
Lekhanh O. Tran
William C. Lumma, Jr.
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to AU16942/95A priority Critical patent/AU1694295A/en
Publication of WO1995020389A1 publication Critical patent/WO1995020389A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • This case is related to Merck Cases 18429, 18429IA and 18727.
  • This case is a continuation-in-part of Merck Case 18793IA, filed April 27, 1993, U.S.S.N. 08/054,805, which is a continuation-in-part of Merck Case 18793, filed August 7, 1992, U.S.S.N. 07/926,607.
  • a retrovirus designated human immunodeficiency virus is the etiological agent of the complex disease that includes progressive destruction of the immune system (acquired immune deficiency syndrome; AIDS) and degeneration of the central and peripheral nervous system.
  • This virus was previously known as LAV, HTLV-III, or ARV.
  • a common feature of retrovirus replication is reverse transcription of the RNA genome by a virally encoded reverse transcriptase to generate DNA copies of HIV sequences, a required step in viral replication. It is known that some compounds are reverse transcriptase inhibitors and are effective agents in the treatment of AIDS and similar diseases, e.g., azidothymidine or AZT.
  • Nucleotide sequencing of HIV shows the presence of a pol gene in one open reading frame [Ratner, L. et al., Nature, 313, 277 (1985)].
  • Amino acid sequence homology provides evidence that the pol sequence encodes reverse transcriptase, an endonuclease and an HIV protease [Toh, H. et al., EMBO J. 4, 1267 (1985); Power, M.D. et al., Science. 231 , 1567 (1986); Pearl, L.H. et al., Nature 329, 351 (1987)].
  • transcriptase and its resistant varieties
  • the prevention of infection by HIV the prevention of infection by HIV, the treatment of infection by HIV and in the treatment of AIDS and/or ARC, either as compounds, pharmaceutically acceptable salts (when appropriate), pharmaceutical composition ingredients, whether or not in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines.
  • pharmaceutical composition ingredients whether or not in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines.
  • This invention is concerned with compounds of Formula I, combinations thereof, or pharmaceutically acceptable salts thereof, in the inhibition of HIV reverse transcriptase and its resistant varieties, the prevention or treatment of infection by HIV and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).
  • Compounds of Formula I are defined as follows:
  • X is halo
  • X 1 is trihalomethyl, or pentahaloethyl
  • Z is O
  • This invention also encompasses a pharmaceutical composition useful for inhibiting HIV reverse transcription, comprising an effective amount of a compound of Formula II,
  • X is halo
  • X 1 is trihalomethyl; pentahaloethyl; C 2-5 alkyl;
  • Z is O or S; R is
  • Preferred compounds include Compounds 37.2, 4, 2, 5 and 24 of Table I below, in order of descending degree of preference.
  • the compounds of the present invention may have asymmetric centers and may occur, except when specifically noted, as racemates, racemic mixtures or as individual diastereomers, or enantiomers, with all isomeric forms being included in the present invention.
  • (+/-) is intended to encompass (+) optical isomers or (-) optical isomers or mixtures thereof.
  • variable e.g., R
  • its definition on each occurrence is independent of its definition at every other occurrence.
  • alkyl is intended to include both branched- and straight-chain saturated aliphatic
  • alkenyl is intended to cover both branched- and straight chain alkyl groups with at least one carbon-carbon double bond;
  • alkynyl is intended to cover both branched- and straight chain alkyl groups with at least one carbon-carbon triple bond.
  • Halogen or “halo” as used herein, means fluoro, chloro, bromo and iodo.
  • aryl is intended to mean phenyl, naphthyl, tetrahydronaphthyl, biphenyl, phenanthryl, anthryl or acenaphthyl.
  • heterocycle or heterocyclic represents a stable 5- to 7-membered monocyclic or stable 8- to 11-membered bicyclic heterocyclic ring which is either saturated, partially unsaturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • heterocyclic elements examples include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, pyrazinyl,
  • benzoxazolyl furyl, tetrahydrofuryl, benzofuranyl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl.
  • the compounds of the present invention can be synthesized by the following methods.
  • the general method typically involves cyclization on a benzene nucleus as a final step. See Scheme I.
  • the amino group of parachloroaniline is first protected with, e.g., pivaloyl chloride, to give 2.
  • Other less preferable amino protecting groups include t-butoxycarbonyl, acetate or isovaleroyl groups.
  • About 2 equivalents of an alkyllithium are then reacted with 2, preferably n-butyl lithium. No other organo metallic compounds are suitable for this metalation step. Subsequently, reaction with CF 3 COOEt followed by quenching gives 3.
  • the Grignard reagent must be a salt of a divalent cation, e.g., Mg ++ or Zn ++ .
  • Monovalent cations are found unsuitable, such as Li + or Na + .
  • Suitable solvents include but are not limited to THF or ether. A wide range of temperature conditions are allowed between about 0°C and about room temperature.
  • Ring closure to produce the compounds of the present invention 5 is accomplished with condensing agents such as 1,1'-carbonyldiimidazole, phosgene, dimethylcarbonate, diphenylcarbonate, or di-(paranitrophenyl)carbonate. Cyclization can be accomplished with any of these compounds, as well as a wide variety of others.
  • Scheme IA A specific instance of Scheme I is provided in Scheme IA. It charts the synthesis of L-741,211, which is a racemate of Compound 37.2, as further provided in Example 6.
  • Scheme II provides one method for derivatizing acetylene substitutions at the 4-position of the benzoxazine nucleus.
  • Compound 6 is metalized, then a zinc salt is added.
  • the catalyst tetrakis (triphenylphosphine)palladium(0) complexed with CuI is employed to give 7.
  • Scheme III illustrates substitution of a 4-acetylene group with an N-containing heterocycle.
  • the Mannich reaction involves a condensation reaction of formaldehyde with the heterocycle, e.g., pyrrohdine. Substitution on the terminal carbon follows in the presence of CuI as catalyst.
  • Scheme IV illustrates the resolution of optical isomers of the compounds of Formula I or Formula II.
  • (-) camphanic acid is the resolving agent.
  • a wide variety of other resolving agents are suitable, including O-methyl mandelic acid chloride or Mosher's reagent. It is apparent to the skilled artison how to separate such isomers.
  • Scheme IVA is specifically adapted to the resolution of L-741,211 in the isolation of L-743,726. See Scheme IVA, and Example 6.
  • the compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds.
  • the compounds of this invention are useful for isolating enzyme mutants, which are excellent screening tools for more powerful antiviral compounds.
  • the compounds of this invention are useful in establishing or determining the binding site of other antivirals to HIV reverse transcriptase, e.g., by competitive inhibition.
  • the compounds of this invention are commercial products to be sold for these purposes.
  • the compounds of the present inventions are useful in the inhibition of HIV reverse transcriptase, the prevention or treatment of infection by human immunodeficiency virus (HIV) and the treatment of consequent pathological conditions such as AIDS.
  • Treating AIDS or preventing or treating infection by HIV is defined as including, but not limited to, treating a wide range of States of HIV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HIV.
  • the compounds of this invention are useful in treating infection by HIV after suspected past exposure to HIV by e.g., blood transfusion, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.
  • the particular advantage of the compounds of this invention is their potent inhibition against HIV reverse transcriptase rendered resistant to other antivirals, such as L-697,661, which is 3- ([(4,7-dichloro-1,3-benzoxazol-2-yl)methyl]-amino)-5-ethyl-6-methyl-pyridin-2(1H)-one; or L-696,229, which is 3-[2-(1,3-benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-pyridin-2(1H)-one; or AZT.
  • L-697,661 which is 3- ([(4,7-dichloro-1,3-benzoxazol-2-yl)methyl]-amino)-5-ethyl-6-methyl-pyridin-2(1H)-one
  • L-696,229 which is 3-[2-(1,3-benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-
  • the compounds of the present invention may be administered orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrastemal injection or infusion techniques), by inhalation spray, or rectally, in dosage unit formulations containing conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles.
  • a pharmaceutical composition comprising a pharmaceutical carrier and a therapeutically-effective amount of a compound of the present invention.
  • compositions may be in the form of orally-administrable suspensions or tablets; nasal sprays; sterile injectable preparations, for example, as sterile injectable aqueous or oleagenous suspensions or suppositories.
  • compositions When administered orally as a suspension, these compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and
  • these compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art.
  • compositions When administered by nasal aerosol or inhalation, these compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
  • the injectable solutions or suspensions may be formulated according to known art, using suitable non-toxic, parenterally-acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
  • suitable non-toxic, parenterally-acceptable diluents or solvents such as mannitol, 1,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
  • these compositions When rectally administered in the form of suppositories, these compositions may be prepared by mixing the drug with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquidify and/or dissolve in the rectal cavity to release the drug.
  • a suitable non-irritating excipient such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquidify and/or dissolve in the rectal cavity to release the drug.
  • the compounds of this invention can be administered orally to humans in a dosage range of 1 to 100 mg/kg body weight in divided doses.
  • One preferred dosage range is 0.1 to 10 mg/kg body weight orally in divided doses.
  • Another preferred dosage range is 0.1 to 20 mg/kg body weight orally in divided doses.
  • a preferred dosage range is 0.1 to 20 mg/kg body weight for the compounds of this invention administered orally in divided doses, and 50 mg to 5 g/kg body weight for nucleoside analogs administered orally in divided doses.
  • the present invention is also directed to combinations of the HIV reverse transcriptase inhibitor compounds with one or more agents useful in the treatment of AIDS.
  • the compounds of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of the AIDS antivirals, immunomodulators, antunfectives, or vaccines, such as those in the following Table.
  • Ganciclovir (Palo Alto, CA) peripheral CMV
  • NC Kaposi's sarcoma, asymptomatic HTV infection, less severe HIV disease, neurological involvement, in combination with therapies.
  • Ribavirin (Costa Mesa, CA) positive, LAS, ARC
  • HIV Core Particle Rorer seropositive HIV Immunostimulant (Ft. Washington, PA) Drug Name Manufacturer Indication
  • Interleukin-2 (Nutley, NJ) combination w/AZT
  • MethionineTNI Pharmaceutical AIDS, ARC
  • Granulocyte Amgen AIDS in combination Colony Stimulating (Thousand Oaks, CA) w/AZT
  • Tumor Necrosis Genentech ARC in combination Factor; TNF (S. San Francisco, CA) w/gamma Interferon
  • Isethionate (IM & IV) (Rosemont, IL)
  • R51211 (Piscataway, NJ) cryptococcal meningitis
  • Erythropoietin (Raritan, NJ) with AZT therapy
  • a compound of Formula I or Formula II may be suitably administered in combination with a nucleoside analog having known biological activity against HIV reverse transcriptase.
  • Appropriate nucleoside analogs are generally chain terminators and include AZT, ddC, ddI, D4T, HEPT and 3'-fluoro-2',3'-dideoxythymidine.
  • AZT is synthesized by the methods of J.P. Horwitz et al., J. Org. Chem. 29, 2076 (1964); R.P. Glinski et al., J. Org. Chem. 38, 4299 (1973); C.K. Chu et al., Tetrahedron Letters 29. 5349 (1988).
  • Application of AZT as a therapeutic drug in the treatment of AIDS is disclosed in U.S. 4,724,232.
  • the compound ddC is synthesized by the methods of J.P. Horwitz et al., J. Org. Chem. 32, 817 (1967); R. Marumoto, Chem. Pharm. Bull. 22, 128 (1974); and T.-S. Lin et al.. J. Med. Chem. 30, 440 (1987).
  • D4T is synthesized by the methods of Herdewijn, P. et al., J. Med. Chem. 30. 1270 (1987).
  • HEPT is synthesized by the methods of Miyasaka, T. et al., J. Med. Chem. 32. 2507 (1989); and A. Rosowskv. J. Med. Chem. 24. 1177 (1981).
  • the synthesis of ddC, ddl and AZT are also described in EPO 484071.
  • the compound 3'-fluoro-2',3'-dideoxythymidine is synthesized by the procedures of Herdewijn, P. et al., J. Med. Chem. 30, 1270 (1987).
  • the compound L-735,524 is N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarbamoyl)-piperazinyl))-pentaneamide, or
  • L-697,661 or '661' is 3-([4,7-dichloro-1,3-benzoxazol-2-yl)methyl]-amino)-5-ethyl-ethyl-6-methyl-pyridin-2(1H)-one;
  • L-696,229 is 3-[2-(1,3-benzoxazol-2-yl)-ethyl]-5-ethyl-6-methyl-pyridin-2(1H)-one.
  • the synthesis of L-697,661 and L-696,229 is described in EPO 484071, and EPO 462800, both herein inco ⁇ orated by reference.
  • L-735,524 is synthesized by the methods of EP 0541168, herein incorporated by reference for these pu ⁇ oses.
  • Preferred combinations are simultaneous, intermittent, or alternating treatments of L-743,726 with or without an inhibitor of HIV protease.
  • An optional third component in the combination is a
  • nucleoside inhibitor of HIV reverse transcriptase such as AZT, ddC or ddl.
  • a preferred inhibitor of HTV protease is L-735,524.
  • Other preferred inhibitors of HTV reverse transcriptase include L-697,661. These combinations may have synergistic effects on limiting the spread of HIV. Preferred combinations include the following: (1) L-743,726 with L-735,524, and, optionally any of L-697,661, AZT, ddl or ddC; (2) L-743,726 and any of L-697,661, AZT, ddI or ddC.
  • Step B 1-(2-amino-5-chlorophenyl)-2,2,2-trifluoroethanone
  • N-(4-chlorophenyl)-2,2-dimethylpropanamide 100 g, 472 mmol
  • dry THF 1L
  • n-butyllithium 387 mL of a 2.5 M solution in hexanes, 968 mmol
  • the n-butyllithium solution was added dropwise to the amide solution slowly over 1 h, maintaining the temperature below +5°C.
  • Step C (+/-) 2-(2-Amino-5-chlorophenyl)-1,1,1-trifluoro-5-hexen- 2-ol
  • Step A 2-(2-amino-5-chlorophenyl)-1,1,1-trifluoro-3-butyn-2-ol
  • Step B (+/-) 6-Chloro-4-ethynyl-4-(1,1,1-trifluoromethyl)-1 ,4- dihydro-2H-3,1 -benzoxazin-2-one
  • a THF solution of 2-(2-amino-5-chlorophenyl)-1,1 ,1-trifluoro-3-butyn-2-ol (5.0 g, 20.0 mmol in 225 mL THF) was treated with 1,1 '-carbonyldiimidazole (13.0 g, 80.0 mmol) and heated in an oil bath at 60°C for 17 h.
  • the THF was removed in vacuo. the residue dissolved in ethyl acetate then washed with 10% citric acid, sodium bicarbonate, water and brine before drying over sodium sulfate.
  • Step A 1-(2-amino-5-chlorophenyl)-2-chloro-2,2-difluoroethanone
  • N-(4-chlorophenyl)-2,2-dimethylpropanamide 10 g, 47.2 mmol
  • dry THF 100 mL
  • This solution was cooled in an ice bath to 0°C and the addition funnel was charged with n-butyllithium (38.7 mL of a 2.5 M solution in hexanes, 96.8 mmol).
  • n-butyllithium solution was added dropwise to the amide solution slowly over 1 h, maintaining the temperature below +5°C.
  • Step C (+/-) 4-(1-Chloro-1,1-difluoromethyl)-4-(2-phenylethynyl)-6-chloro-1 ,4-dihydro-2H-3, 1-benzoxazin-2-one
  • (+/-) 2-(2-amino-5-chlorophenyl)-4-phenyl-1-chloro-1,1-difluoro-3-butyn-2-ol (0.81 g, 2.37 mmol), dry THF (25 mL), and 1,1'-carbonyldiimidazole (1.919 g, 11.84 mmol).
  • Step A 2-(2-Amino-5-chlorophenyl)-4-phenyl-1,1 ,1-trifluoro-3- butyn-2-ol
  • a solution of lithio phenylacetylide prepared from 4.83 mL of phenylacetylene (0.044 mol) and 17.2 mL of a 2.5 N solution of n-butyllithium in hexane (0.043 mol) in 50 mL of THF at -78°C, was treated with 11.4 g of magnesium bromide etherate (0.044 mol) over 5 minutes. The mixture was allowed to warm to -20°C and stirring under argon was continued for 30 minutes.
  • Step C 6-Chloro-1-(1S)-camphanoyl-4-phenylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
  • camphanic acid chloride (2.07 g, 9.55 mmol) in 60 mL of dry
  • Step D (-) 6-Chloro-4-phenylethynyl-4-trifluoromethyl-1,4- dihydro-2H-3,1-benzoxazin-2-one
  • Step E (+) 6-Chloro-4-phenylethynyl-4-trifluoromethyl 1 ,4- dihydro-2H-3,1-benzoxazin-2-one (Compound 3)
  • Step A 2-(2-Amino-5-chlorophenyl)-4-cyclopropyl-1,1,1- trifluoro-3-butyn-2-ol
  • a solution of bromomagnesium cyclopropylacetylide was prepared from 23 g of cyclopropylacetylene (0.348 mol) in 250 mL of THF by dropwise addition of 116 mL of a 3.0 M solution of
  • Step B ( ⁇ ) 6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4- dihydro-2H-3,1-benzoxazin-2-one (L-741.211)
  • Step C 6-Chloro-1-(1S)-camphanoyl-4-cyclopropylethynyl-4- trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
  • Step D (-) 6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4- dihydro-2H-3,1-benzoxazin-2-one (L-743,726, Compound
  • the assay measures the inco ⁇ oration of tritiated deoxyguanosine monophosphate by recombinant HTV reverse
  • HIV RT R HIV RT R
  • RT R acid-precipitable cDNA
  • the inhibitors of the present invention inhibit this incorporation.
  • the assays were carried out in 55 mM Tris (pH 8.2)-30 mM KCl-30 mM MgCl 2 -1 mM dithiothreitol-20 ⁇ g of rC:dG 12-18 (Pharmacia) per ml-8 mM [ 3 H]dGTP (New England Nuclear)-0.01% Triton X- 100-50 mM ethylene glycol-bis( ⁇ -amino-ethyl ether)-N,N,N',N'-tetraacetic acid (EGTA)-l mg of bovine serum albumin per ml. After 60 min of incubation at 37°C, acid-precipitable material was collected onto glass fiber filters by using a semiautomatic cell harvester.
  • Bacterial cell extracts containing RT were diluted to within the linear range of the assay, and activity was determined in the presence and absence of inhibitor.
  • Purified HIV-1 RT heterodimer produced in E. coli also served as a control. Results are determined as inhibitor concentration to give 50% inhibition (IC 50 wt), in nanomoles/liter.
  • A17 RT was employed in the assay.
  • A17 RT is resistant to various aminopyridones, as described in Nunberg, J.H. et al., J. Virol. 65, 4887 (1991). Results are measured as IC 50 dm in nanomoles/liter.
  • Inhibition of the spread of HIV in cell culture was measured according to Nunberg, J. H. et al., J. Virol. 65, 4887 (1991).
  • MT-4 T-lymphoid cells were infected with HIV-1 (wild-type, unless otherwise indicated) by using a predetermined inoculum, and cultures were incubated for 24 h. At this time, ⁇ 1 % of the cells were positive by indirect immunofluorescence. Cells were then extensively washed and distributed into 96-well culture dishes. Serial twofold dilutions of inhibitor were added to the wells, and cultures were continued for 3 additional days. At 4 days postinfection, 100% of the cells in control cultures were infected. HIV-1 p24 accumulation was directly correlated with virus spread.
  • the cell culture inhibitory concentration was defined as the inhibitor concentration in
  • nanomoles/liter which reduced the spread of infection by at least 95%, or CIC 95 .
  • DM is the double mutant, as discussed in the reverse transcriptase assay.
  • RT-2 is the reverse transcriptase of HTV-2.
  • MT cells were infected at Day 0 at a concentration of 250,000 per ml with a 1:1000 dilution of HTV-1 strain IIIb stock (final 125 pg p24/ml; sufficient to yield ⁇ 1% infected cells on day 1 and 25-100% on day 4).
  • Cells were infected and grown in the following medium: RPMI 1640 (Whittaker BioProducts), 10% inactivated fetal bovine serum, 4 mM glutamine (Gibco Labs) and 1:100 Penicillin-Streptomycin (Gibco Labs).
  • the mixture was incubated overnight at 37 °C in 5% C ⁇ 2 atmosphere.
  • a matrix of nanomolar range concentrations of the pairwise combinations was prepared.
  • aliquots of 125 ⁇ l of inhibitors were added to equal volumes of HTV-infected MT-4 cells (50,000 per well) in a 96-well microtiter cell culture plate. Incubation was continued for 3 days at 37°C in 5% C ⁇ 2 atmosphere.
  • the settled cells were resuspended and 125 ⁇ l harvested into a separate microtiter plate. The supernatant was assayed for HTV p24 antigen.
  • the concentration of HTV p24 antigen was measured by an enzyme immunoassay, described as follows. Aliquots of p24 antigen to be measured were added to microwells coated with a monoclonal antibody specific for HIV core antigen. The microwells were washed at this point, and at other appropriate steps that follow. Biotinylated HIV-specific antibody was then added, followed by conjugated strepavidin-horseradish peroxidase. A color reaction occurs from the added hydrogen peroxide and tetramethylbenzidine substrate. Color intensity is proportional to the concentration of HTV p24 antigen.
  • Pairwise combinations of inhibitors were found to exhibit markedly enhanced inhibition of virus spread, in comparison to each inhibitor alone, or in comparison to merely additive inhibition of each inhibitor.
  • fractional inhibitory concentration ratios were calculated according to Elion, et. ah J. Biol. Chem., 208 477 (1954).
  • the minimum sum of FICS which is the maximum synergy, was determined for various pairwise combinations.
  • an average sum of the FICS is calculated, which is the average synergy. See Table S.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Certaines benzoxazinones sont efficaces en tant qu'inhibiteurs de transcriptase inverse du VIH (y compris ses variétés résistantes), ainsi que pour la prévention ou le traitement de l'infection par VIH et pour le traitement du SIDA, en tant que composés, sels pharmaceutiquement acceptables, ingredients de compositions pharmaceutiques, combinés ou non à d'autres agents antiviraux, immunomodulateurs, antibiotiques ou vaccins. L'invention concerne également des procédés de traitement du SIDA, ainsi que des procédés de prévention ou de traitement de l'infection par VIH.
PCT/US1995/001148 1994-01-28 1995-01-24 Benzoxazinones en tant qu'inhibiteurs de transcriptase inverse du vih WO1995020389A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU16942/95A AU1694295A (en) 1994-01-28 1995-01-24 Benzoxazinones as inhibitors of hiv reverse transcriptase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18800594A 1994-01-28 1994-01-28
US188,005 1994-01-28

Publications (1)

Publication Number Publication Date
WO1995020389A1 true WO1995020389A1 (fr) 1995-08-03

Family

ID=22691388

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/001148 WO1995020389A1 (fr) 1994-01-28 1995-01-24 Benzoxazinones en tant qu'inhibiteurs de transcriptase inverse du vih

Country Status (2)

Country Link
AU (1) AU1694295A (fr)
WO (1) WO1995020389A1 (fr)

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034566A2 (fr) * 1996-03-19 1997-09-25 G.D. Searle & Co. Cetones electrophiles pour le traitement d'infections a herpesvirus
WO1998004535A1 (fr) * 1996-07-26 1998-02-05 Du Pont Pharmaceuticals Company Synthese pratique de benzoxazinones utiles comme inhibiteurs de la transcriptase inverse du vih
WO1998051676A1 (fr) * 1997-05-16 1998-11-19 Merck & Co., Inc. Reaction d'addition enantioselective efficace a reactif de type complexe organate-zinc
WO1999011635A1 (fr) * 1997-09-02 1999-03-11 Du Pont Pharmaceuticals Company 5,5-disubstitues-1,5-dihydroxyx-4,1-benzoxazepine-2(3h)-ones utiles comme inhibiteurs de la transcriptase inverse du vih
US5925789A (en) * 1997-04-07 1999-07-20 Dupont Pharmaceuticals Company Asymmetric synthesis of benzoxazinones
US5932726A (en) * 1996-12-16 1999-08-03 Dupont Pharmaceuticals Company Asymmetric synthesis of benzoxazinones
WO1999040920A1 (fr) * 1998-02-17 1999-08-19 Du Pont Pharmaceuticals Company Formulations orales liquides d'inhibiteurs de transcriptase inverse de vih a base de benzoxazinones
WO1999040921A2 (fr) * 1998-02-17 1999-08-19 Du Pont Pharmaceuticals Company Formulations orales liquides d'inhibiteurs de transcriptase inverse de vih a base de benzoxazinones
WO1999050253A1 (fr) * 1998-03-27 1999-10-07 Du Pont Pharmaceuticals Company 3,4-dihydro-2(1h)-quinazolinthiones substitues en 4,4, leur preparation et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
WO1999051239A1 (fr) * 1998-04-07 1999-10-14 Du Pont Pharmaceuticals Company Procede utilisant des super-desintegrants dans la preparation de capsules ou de comprimes d'efavirenz a dissolution rapide
WO1999061026A1 (fr) * 1998-05-27 1999-12-02 Merck & Co., Inc. Formulation de comprime d'efavirenz
WO1999064405A1 (fr) * 1998-06-11 1999-12-16 Du Pont Pharmaceuticals Company Efavirenz sous forme cristalline
EP0975609A1 (fr) * 1997-02-05 2000-02-02 Merck & Co., Inc. Procede de cristallisation d'un inhibiteur de transcriptase inverse utilisant un antisolvant
LT4646B (lt) 1996-12-16 2000-04-25 Dupont Pharmaceuticals Company Benzoksazinonų asimetrinė sintezė
US6072094A (en) * 1997-08-06 2000-06-06 Merck & Co., Inc. Efficient synthesis of cyclopropylacetylene
WO2000066571A1 (fr) * 1999-05-04 2000-11-09 American Home Products Corporation Derives de cyclocarbamate utilises comme modulateurs du recepteur de progesterone
WO2000066570A1 (fr) * 1999-05-04 2000-11-09 American Home Products Corporation Derives de cyclothiocarbamate tenant lieu de modulateurs du recepteur de progesterone
US6147210A (en) * 1996-07-26 2000-11-14 Dupont Pharmaceuticals Company Practical synthesis of benzoxazinones useful as HIV reverse transcriptase inhibitors
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6313364B1 (en) 1999-10-28 2001-11-06 Merck & Co., Inc. Synthesis of cyclopropaneacetylene using a catalytic decarboxylation reaction
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6552239B1 (en) 1999-10-28 2003-04-22 Merck & Co., Inc. Synthesis of cyclopropaneacetylene by a one-pot process
EP1332757A1 (fr) * 1998-05-27 2003-08-06 MERCK & CO. INC. Formulation de comprimé d' efavirenz
US6639071B2 (en) 1997-02-05 2003-10-28 Merck & Co., Inc. Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
US6673784B1 (en) 1996-03-19 2004-01-06 G. D. Searle & Co. Electrophilic ketones for the treatment of herpesvirus infections
US6673372B1 (en) 1998-06-11 2004-01-06 Bristol-Myers Squibb Pharma Company Crystalline Efavirenz
EA004511B1 (ru) * 1999-05-04 2004-04-29 Америкэн Хоум Продактс Корпорейшн Циклотиокарбаматные производные в качестве модуляторов рецептора прогестерона
SG114650A1 (en) * 1999-05-04 2005-09-28 American Home Prod Cyclocarbamate derivatives as progesterone receptor modulators
US7060294B2 (en) 1998-05-27 2006-06-13 Merck & Co., Inc Compressed tablet formulation
WO2009044788A1 (fr) * 2007-10-05 2009-04-09 Banyu Pharmaceutical Co., Ltd. Dérivé de benzoxazinone
US8115032B2 (en) 2009-04-09 2012-02-14 Lonza Ltd. Process for the synthesis of a propargylic alcohol
WO2012048884A1 (fr) 2010-10-14 2012-04-19 Lonza Ltd Procédé de synthèse de carbamates cycliques
WO2012048887A1 (fr) 2010-10-14 2012-04-19 Lonza Ltd Procédé de synthèse de d'alcools propargyliques chiraux cycliques
EP2471783A1 (fr) 2010-12-23 2012-07-04 Esteve Química, S.A. Nouvelle forme polymorphe de l'éfavirenz
WO2012097511A1 (fr) * 2011-01-19 2012-07-26 Lonza Ltd Dmp-266 par cyclisation
US8283502B2 (en) 2009-04-09 2012-10-09 Lonza Ltd. Autocatalytic process for the synthesis of chiral propargylic alcohols
DE202015104551U1 (de) 2015-08-27 2015-12-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Reaktoren für die Herstellung von Efavirenz sowie Zwischenprodukte

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1135899A (en) * 1966-08-03 1968-12-04 Farmaceutici Italia 3,1-benzoxazin-2-ones

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1135899A (en) * 1966-08-03 1968-12-04 Farmaceutici Italia 3,1-benzoxazin-2-ones
US3526621A (en) * 1966-08-03 1970-09-01 Farmaceutical Italia Soc Substituted 3,1-benzoxazin-2-one

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADVANCES IN MASS SPECTROMETRY, Volume 7B, issued November 1978, B. GIOIA et al., "Identification of the Metabolites of Brofoxine in Rat Urine, Mass Spectrometry Studies", pages 1622-1627. *
FARMACO, Volume 35, Number 1, issued 1980, M. MENOZZI et al., "Interazione Degli Psicofarmaci Brofoxine E Caroxazone Con Le Proteine Plasmatiche", pages 79-88. *

Cited By (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034566A3 (fr) * 1996-03-19 1998-01-08 Cetones electrophiles pour le traitement d'infections a herpesvirus
US6673784B1 (en) 1996-03-19 2004-01-06 G. D. Searle & Co. Electrophilic ketones for the treatment of herpesvirus infections
WO1997034566A2 (fr) * 1996-03-19 1997-09-25 G.D. Searle & Co. Cetones electrophiles pour le traitement d'infections a herpesvirus
WO1998004535A1 (fr) * 1996-07-26 1998-02-05 Du Pont Pharmaceuticals Company Synthese pratique de benzoxazinones utiles comme inhibiteurs de la transcriptase inverse du vih
US6348616B1 (en) 1996-07-26 2002-02-19 Michael Ernest Pierce Practical synthesis of benzoxazinones useful as HIV reverse transcriptase inhibitors
US6147210A (en) * 1996-07-26 2000-11-14 Dupont Pharmaceuticals Company Practical synthesis of benzoxazinones useful as HIV reverse transcriptase inhibitors
LT4646B (lt) 1996-12-16 2000-04-25 Dupont Pharmaceuticals Company Benzoksazinonų asimetrinė sintezė
US5932726A (en) * 1996-12-16 1999-08-03 Dupont Pharmaceuticals Company Asymmetric synthesis of benzoxazinones
US6939964B2 (en) 1997-02-05 2005-09-06 Merck & Co., Inc. Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
CZ304186B6 (cs) * 1997-02-05 2013-12-11 Merck Sharp & Dohme Corp. Krystalická forma I inhibitoru na bázi benzoxazinu a zpusob její výroby
US6639071B2 (en) 1997-02-05 2003-10-28 Merck & Co., Inc. Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
EP0975609A4 (fr) * 1997-02-05 2001-02-21 Merck & Co Inc Procede de cristallisation d'un inhibiteur de transcriptase inverse utilisant un antisolvant
CZ297535B6 (cs) * 1997-02-05 2007-01-03 Merck & Co., Inc. Způsob krystalizace inhibitoru na bázi benzoxazinonu
EP0975609A1 (fr) * 1997-02-05 2000-02-02 Merck & Co., Inc. Procede de cristallisation d'un inhibiteur de transcriptase inverse utilisant un antisolvant
US6040480A (en) * 1997-04-07 2000-03-21 Du Pont Pharmaceuticals Company Asymmetric synthesis of benzoxazinones
US5925789A (en) * 1997-04-07 1999-07-20 Dupont Pharmaceuticals Company Asymmetric synthesis of benzoxazinones
WO1998051676A1 (fr) * 1997-05-16 1998-11-19 Merck & Co., Inc. Reaction d'addition enantioselective efficace a reactif de type complexe organate-zinc
US6015926A (en) * 1997-05-16 2000-01-18 Merck & Co., Inc. Efficient enantioselective addition reaction using an organozinc reagent
CN1106389C (zh) * 1997-05-16 2003-04-23 麦克公司 应用有机锌试剂的有效对映选择性加成反应
CZ297968B6 (cs) * 1997-05-16 2007-05-09 Merck And Co., Inc. Zpusob výroby klícového meziproduktu
US6072094A (en) * 1997-08-06 2000-06-06 Merck & Co., Inc. Efficient synthesis of cyclopropylacetylene
WO1999011635A1 (fr) * 1997-09-02 1999-03-11 Du Pont Pharmaceuticals Company 5,5-disubstitues-1,5-dihydroxyx-4,1-benzoxazepine-2(3h)-ones utiles comme inhibiteurs de la transcriptase inverse du vih
WO1999040921A2 (fr) * 1998-02-17 1999-08-19 Du Pont Pharmaceuticals Company Formulations orales liquides d'inhibiteurs de transcriptase inverse de vih a base de benzoxazinones
WO1999040920A1 (fr) * 1998-02-17 1999-08-19 Du Pont Pharmaceuticals Company Formulations orales liquides d'inhibiteurs de transcriptase inverse de vih a base de benzoxazinones
US6235733B1 (en) 1998-02-17 2001-05-22 Dupont Pharmaceuticals Company Oral liquid formulations of benzoxazinones HIV reverse transcriptase inhibitors
WO1999040921A3 (fr) * 1998-02-17 1999-11-04 Du Pont Pharm Co Formulations orales liquides d'inhibiteurs de transcriptase inverse de vih a base de benzoxazinones
US6127375A (en) * 1998-03-27 2000-10-03 Dupont Pharmaceuticals Company 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinthiones useful as HIV reverse transcriptase inhibitors
WO1999050253A1 (fr) * 1998-03-27 1999-10-07 Du Pont Pharmaceuticals Company 3,4-dihydro-2(1h)-quinazolinthiones substitues en 4,4, leur preparation et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
US6238695B1 (en) 1998-04-07 2001-05-29 Dupont Pharmaceuticals Company Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
KR100634253B1 (ko) * 1998-04-07 2006-10-16 브리스톨-마이어스 스퀴브 파마 컴파니 초강력 붕해제를 사용한 고속-용해 에파비렌즈 캡슐 또는정제 및 그의 제조 방법
AU756422B2 (en) * 1998-04-07 2003-01-09 Du Pont Pharmaceuticals Company Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
WO1999051239A1 (fr) * 1998-04-07 1999-10-14 Du Pont Pharmaceuticals Company Procede utilisant des super-desintegrants dans la preparation de capsules ou de comprimes d'efavirenz a dissolution rapide
US6555133B2 (en) 1998-04-07 2003-04-29 Bristol-Myers Squibb Company Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
WO1999061026A1 (fr) * 1998-05-27 1999-12-02 Merck & Co., Inc. Formulation de comprime d'efavirenz
US7595063B2 (en) 1998-05-27 2009-09-29 Merck & Co., Inc. Compressed tablet formulation
EP1332757A1 (fr) * 1998-05-27 2003-08-06 MERCK & CO. INC. Formulation de comprimé d' efavirenz
US7060294B2 (en) 1998-05-27 2006-06-13 Merck & Co., Inc Compressed tablet formulation
AU758114C (en) * 1998-06-11 2003-10-30 Bristol-Myers Squibb Pharma Company Crystalline efavirenz
US6673372B1 (en) 1998-06-11 2004-01-06 Bristol-Myers Squibb Pharma Company Crystalline Efavirenz
WO1999064405A1 (fr) * 1998-06-11 1999-12-16 Du Pont Pharmaceuticals Company Efavirenz sous forme cristalline
AU758114B2 (en) * 1998-06-11 2003-03-13 Bristol-Myers Squibb Pharma Company Crystalline efavirenz
JP2002517487A (ja) * 1998-06-11 2002-06-18 デュポン ファーマシューティカルズ カンパニー 結晶性エファビレンツ
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
EA004511B1 (ru) * 1999-05-04 2004-04-29 Америкэн Хоум Продактс Корпорейшн Циклотиокарбаматные производные в качестве модуляторов рецептора прогестерона
US6436929B1 (en) 1999-05-04 2002-08-20 Wyeth Cyclothiocarbamate derivatives as progesterone receptor modulators
US6441019B2 (en) 1999-05-04 2002-08-27 Wyeth Cyclocarbamate and cyclic amide derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6503939B2 (en) 1999-05-04 2003-01-07 Wyeth Combination regimens using 3,3-substituted indoline derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6521657B2 (en) 1999-05-04 2003-02-18 Wyeth Thio-oxindole derivatives
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6544970B2 (en) 1999-05-04 2003-04-08 Wyeth Cyclic regimens utilizing indoline derivatives
WO2000066571A1 (fr) * 1999-05-04 2000-11-09 American Home Products Corporation Derives de cyclocarbamate utilises comme modulateurs du recepteur de progesterone
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6562857B2 (en) 1999-05-04 2003-05-13 Wyeth Cyanopyrroles
US6566358B2 (en) 1999-05-04 2003-05-20 Wyeth Cyclocarbamate derivatives as progesterone receptor modulators
US6583145B1 (en) 1999-05-04 2003-06-24 Wyeth Thio-oxindole derivatives
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6608068B2 (en) 1999-05-04 2003-08-19 Wyeth Indoline derivatives
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6693103B2 (en) 1999-05-04 2004-02-17 Wyeth 1,2,3,4-tetrahydro-2-thioxo-quinolinyl and 1,2,3,4-tetrahydro-2-oxo-quinolinyl derivatives as progesterone receptor modulators
US6713478B2 (en) 1999-05-04 2004-03-30 Wyeth Cyclocarbamate derivatives as progesterone receptor modulators
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6759408B2 (en) 1999-05-04 2004-07-06 Wyeth Combination regimens using progesterone receptor modulators
US6794373B2 (en) 1999-05-04 2004-09-21 Wyeth Contraceptive methods using benzimidazolones
US6835744B2 (en) 1999-05-04 2004-12-28 Wyeth 3,3-substituted indoline derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6946454B2 (en) 1999-05-04 2005-09-20 Wyeth Thio-oxindole derivatives
SG114650A1 (en) * 1999-05-04 2005-09-28 American Home Prod Cyclocarbamate derivatives as progesterone receptor modulators
US6982261B2 (en) 1999-05-04 2006-01-03 Wyeth Cyanopyrroles
SG120970A1 (en) * 1999-05-04 2006-04-26 Ligand Pharm Inc Cyclothiocarbamate derivatives as progesterone receptor modulators
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US7081457B2 (en) 1999-05-04 2006-07-25 Wyeth Cyclothiocarbamate derivatives as progesterone receptor modulators
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US7846924B2 (en) * 1999-05-04 2010-12-07 Wyeth Llc Cyanopyrroles
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
KR100732692B1 (ko) * 1999-05-04 2007-06-27 와이어쓰 프로게스테론 수용체 조절인자인 시클로티오카르바메이트유도체
WO2000066570A1 (fr) * 1999-05-04 2000-11-09 American Home Products Corporation Derives de cyclothiocarbamate tenant lieu de modulateurs du recepteur de progesterone
US6313364B1 (en) 1999-10-28 2001-11-06 Merck & Co., Inc. Synthesis of cyclopropaneacetylene using a catalytic decarboxylation reaction
US6552239B1 (en) 1999-10-28 2003-04-22 Merck & Co., Inc. Synthesis of cyclopropaneacetylene by a one-pot process
WO2009044788A1 (fr) * 2007-10-05 2009-04-09 Banyu Pharmaceutical Co., Ltd. Dérivé de benzoxazinone
US8283502B2 (en) 2009-04-09 2012-10-09 Lonza Ltd. Autocatalytic process for the synthesis of chiral propargylic alcohols
US8115032B2 (en) 2009-04-09 2012-02-14 Lonza Ltd. Process for the synthesis of a propargylic alcohol
WO2012048884A1 (fr) 2010-10-14 2012-04-19 Lonza Ltd Procédé de synthèse de carbamates cycliques
EP2447255A1 (fr) 2010-10-14 2012-05-02 Lonza Ltd. Processus de synthèse de carbamates cycliques
EP2447247A1 (fr) 2010-10-14 2012-05-02 Lonza Ltd. Processus pour la synthèse d'alcools propargyliques chiraux
WO2012048887A1 (fr) 2010-10-14 2012-04-19 Lonza Ltd Procédé de synthèse de d'alcools propargyliques chiraux cycliques
US8957204B2 (en) 2010-10-14 2015-02-17 Lonza Ltd. Process for the synthesis of cyclic carbamates
EP2471783A1 (fr) 2010-12-23 2012-07-04 Esteve Química, S.A. Nouvelle forme polymorphe de l'éfavirenz
WO2012097511A1 (fr) * 2011-01-19 2012-07-26 Lonza Ltd Dmp-266 par cyclisation
DE202015104551U1 (de) 2015-08-27 2015-12-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Reaktoren für die Herstellung von Efavirenz sowie Zwischenprodukte

Also Published As

Publication number Publication date
AU1694295A (en) 1995-08-15

Similar Documents

Publication Publication Date Title
US5519021A (en) Benzoxazinones as inhibitors of HIV reverse transcriptase
WO1995020389A1 (fr) Benzoxazinones en tant qu'inhibiteurs de transcriptase inverse du vih
CA2101572C (fr) Benzoxaziones utilisees comme inhibiteurs de la transcriptase inverse de vih
US5633405A (en) Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
EP0805790B1 (fr) Synthese amelioree de cyclopropylacetylene
WO1993004047A1 (fr) Derives de quinazoline utilises comme inhibiteurs de transcriptase inverse d'hiv
GB2271566A (en) HIV integrase inhibitors
GB2282808A (en) 3-substituted heterocyclic indoles as inhibitors of HIV reverse transcriptase
CZ289176B6 (cs) Farmaceutický prostředek pro inhibici reverzní transkripce HIV
AU712120B2 (en) HIV protease inhibitors useful for the treatment of AIDS
PL176649B1 (pl) Kombinacja związków farmakologicznie czynnych do zapobiegania infekcji HIV lub leczenia infekcji HIV lub leczenia AIDS albo ARC

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KG KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SI SK TJ TT UA UZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase